Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition

Author:

Martin Seth S1ORCID,Ditmarsch Marc2ORCID,Simmons Mark3,Alp Nicholas3,Turner Traci3,Davidson Michael H24,Kastelein John J P25

Affiliation:

1. Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine , Baltimore, MD 21287 , USA

2. NewAmsterdam Pharma B.V. , Naarden, 1411 DC , The Netherlands

3. Medpace and Medpace Reference Laboratories , Cincinnati, OH 45227 , USA

4. Preventive Cardiology, Department of Cardiology, The University of Chicago Pritzker School of Medicine , Chicago, IL 60637 , USA

5. Department of Vascular Medicine, Academic Medical Center, University of Amsterdam , 1105 AZ Amsterdam The Netherlands

Abstract

Abstract Aims Low-density lipoprotein (LDL-C) lowering is imperative in cardiovascular disease prevention. We aimed to compare accuracy of three clinically-implemented LDL-C equations in a clinical trial of cholesterol ester transfer protein (CETP) inhibition. Methods and results Men and women aged 18–75 years with dyslipidaemia were recruited from 17 sites in the Netherlands and Denmark. Patients were randomly assigned to one of nine groups using various combinations of the CETP inhibitor TA-8995 (obicetrapib), statin therapy, and placebo. In pooled measurements over 12 weeks, we calculated LDL-C by the Friedewald, Martin/Hopkins, and Sampson equations, and compared values with preparative ultracentrifugation (PUC) LDL-C overall and with a special interest in the low LDL-C/high triglycerides subgroup. There were 242 patients contributing 921 observations. Overall median LDL-C differences between estimates and PUC were small: Friedewald, 0.00 (25th, 75th: −0.10, 0.08) mmol/L [0 (−4, 3) mg/dL]; Martin/Hopkins, 0.02 (−0.08, 0.10) mmol/L [1 (−3, 4) mg/dL]; and Sampson, 0.05 (−0.03, 0.15) mmol/L [2 (−1, 6) mg/dL]. In the subgroup with estimated LDL-C <1.8 mmol/L (<70 mg/dL) and triglycerides 1.7–4.5 mmol/L (150−399 mg/dL), the Friedewald equation underestimated LDL-C with a median difference versus PUC of −0.25 (−0.33, −0.10) mmol/L [−10 (−13, −4) mg/dL], whereas the median difference by Martin/Hopkins was 0.00 (−0.08, 0.10) mmol/L [0 (−3, 4) mg/dL] and by Sampson was −0.06 (−0.13, 0.00) mmol/L [−2 (−5, 0) mg/dL]. In this subgroup, the proportion of LDL-C observations <1.8 mmol/L (<70 mg/dL) that were correctly classified compared with PUC was 71.4% by Friedewald vs. 100.0% by Martin/Hopkins and 93.1% by Sampson. Conclusion In European patients with dyslipidaemia receiving a CETP inhibitor, we found improved LDL-C accuracy using contemporary equations vs. the Friedewald equation, and the greatest accuracy was observed with the Martin/Hopkins equation. Registration ClinicalTrials.gov, NCT01970215

Funder

Dezima

Xention

NewAmsterdam Pharma

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Cardiology and Cardiovascular Medicine

Reference36 articles.

1. ESC scientific document group. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

2. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American college of cardiology/American heart association task force on clinical practice guidelines;Grundy;Circulation,2018

3. Interpretation of the evidence for the efficacy and safety of statin therapy;Collins;Lancet North Am Ed,2016

4. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the european atherosclerosis society consensus panel;Ference;Eur Heart J,2017

5. Lipid management for the prevention of atherosclerotic cardiovascular disease;Michos;N Engl J Med,2019

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3